Last reviewed · How we verify
Usual daily opioids
At a glance
| Generic name | Usual daily opioids |
|---|---|
| Also known as | Morphine |
| Sponsor | Rigshospitalet, Denmark |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Enhancing Exercise and Psychotherapy to Treat Pain and Addiction in Opioid Use Disorders ("EXPO" Pilot Trial) (NA)
- A Bundled Intervention - Phase 2 (PHASE4)
- Open-label Placebo for Pain Management in Adolescents and Young Adults Undergoing Bernese Periacetabular Osteotomy (NA)
- Open-label Placebo (COLP) for Pain in Adolescent Idiopathic Scoliosis (AIS) Surgery+Surgical Treatment of Idiopathic Scoliosis (NA)
- Pain Self-Management and Patient-Oriented Dosing for Pain and in Retention Opioid Treatment (PHASE4)
- Low Dose Naltrexone (LDN) for Management of Fatigue in Prostate Cancer Patients on Androgen Deprivation Therapy (ADT) (PHASE2)
- Testing Implementation Strategies to Scale-up a Multicomponent Continuum of Service Intervention for Families Involved in Systems With Parental Opioid and Methamphetamine Use (NA)
- A Bundled Intervention (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Usual daily opioids CI brief — competitive landscape report
- Usual daily opioids updates RSS · CI watch RSS
- Rigshospitalet, Denmark portfolio CI